Grant: CIHR Fellowship
McGill University
$90,000.00
The role of epiregulin and epidermal growth factor receptor in mediating variability in chronic and inflammatory pain
FY 2011-12
Summary
The basic scientific understanding of pain processing and modulation has greatly increased over the past few decades. A recently completed 5-year, $20 million multi-gene association study aiming to identify the genetic risk factors for pain in patients developing temporomandibular disorder (TMD) pain has identified several key genetic changes. TMD refers to a set of conditions that affect the jaw muscles and/or joint and is the second leading cause of chronic pain for people who report facial or head pain. Patients that developed TMD pain showed a preponderance of genetic changes in or near the genes coding for epiregulin (EREG) and the epidermal growth factor receptor (EGFR) on chromosomes, 4 and 7, respectively. Typically, mutations that lead to EGFR overexpression (called upregulation) or overactivity have been associated with tumours, including lung cancer and colorectal cancer. There is no existing evidence that these genes affect pain, but the results from the human association study suggests that this system may in fact play a crucial role in pain processing. In the current proposal we will use genetic and pharmacological tools to determine whether activation or inhibition of these genes affects sensitivity to painful stimuli in laboratory mice. Further to determine whether the EREG/EGFR system is upregulated in chronic pain conditions we will use receptor staining techniques to identify the location of these proteins in pain-related regions of the nervous system. This research is important because it will allow us to further understand nociceptive processing and regulation by targeting a receptor system that has not been studied for its role in pain. These experiments could help with the development of new high affinity drugs for the EREG/EGFR system for use in pain management. Since there are already drugs commercially available for cancer treatment that inhibit EGFR, it is possible that these drugs could have broader therapeutic potential.
Department
Program
CIHR Fellowship
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
242213
Name
Martin Loren J
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
The role of epiregulin and epidermal growth factor receptor in mediating variability in chronic and inflammatory pain
Programtype2
Fellowship Programs
Orgnameinp2
McGill University
Cihramount2
$90,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Dorsal Root Ganglion; Epidermal Growth Factor Receptor; Epiregulin; Genetic; Immunohistochemistry; Inflammation; Intrathecal; Neuropathic; Pain; Tyrosine Kinase
Abstract
The basic scientific understanding of pain processing and modulation has greatly increased over the past few decades. A recently completed 5-year, $20 million multi-gene association study aiming to identify the genetic risk factors for pain in patients developing temporomandibular disorder (TMD) pain has identified several key genetic changes. TMD refers to a set of conditions that affect the jaw muscles and/or joint and is the second leading cause of chronic pain for people who report facial or head pain. Patients that developed TMD pain showed a preponderance of genetic changes in or near the genes coding for epiregulin (EREG) and the epidermal growth factor receptor (EGFR) on chromosomes, 4 and 7, respectively. Typically, mutations that lead to EGFR overexpression (called upregulation) or overactivity have been associated with tumours, including lung cancer and colorectal cancer. There is no existing evidence that these genes affect pain, but the results from the human association study suggests that this system may in fact play a crucial role in pain processing. In the current proposal we will use genetic and pharmacological tools to determine whether activation or inhibition of these genes affects sensitivity to painful stimuli in laboratory mice. Further to determine whether the EREG/EGFR system is upregulated in chronic pain conditions we will use receptor staining techniques to identify the location of these proteins in pain-related regions of the nervous system. This research is important because it will allow us to further understand nociceptive processing and regulation by targeting a receptor system that has not been studied for its role in pain. These experiments could help with the development of new high affinity drugs for the EREG/EGFR system for use in pain management. Since there are already drugs commercially available for cancer treatment that inhibit EGFR, it is possible that these drugs could have broader therapeutic potential.
Competitiondate
201110
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Martin, Loren J
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $90,000~ $0~